Full-Time

Vice President Program Management & Business Operations

Alltrna

Alltrna

11-50 employees

tRNA-based therapies for stop codon readthrough

Compensation Overview

$250k - $330k/yr

+ Annual incentive program

Cambridge, MA, USA

In Person

Bachelor's, Master's

Category
Project & Program Management (1)
Required Skills
Risk Management

Get referred to Alltrna

See people who can refer or advise you

Requirements
  • A BS/MS degree in a scientific discipline, ideally life science or chemistry.
  • At least 15 years of relevant experience in pharma or biotech drug discovery and development, including a comprehensive understanding of preclinical and clinical drug discovery.
  • At least 10 years of program management experience, preferably in early-stage drug discovery and development.
  • Experience leading cross-functional teams, with strong interpersonal and communication skills.
  • Scientific curiosity and passion for discovering new, innovative medicines.
  • Openness to embracing new technologies and digital approaches in drug discovery.
  • A proven track record of driving successful, collaborative drug discovery teams.
Responsibilities
  • Work closely with the Chief Medical Officer to lead the program team for AP003 and future programs, establishing scientific rigor, open debate, collaborative teamwork, urgency, and accountability.
  • Use comprehensive knowledge of the drug discovery process to guide program teams in defining scientific questions, program strategy, objectives, deliverables, cross-functional plans, timelines, and budgets.
  • Identify bottlenecks, risks, and issues and proactively develop mitigation proposals with team members.
  • Ensure key decisions are identified and assessed for impacts, with alternative scenarios developed and evaluated where appropriate.
  • Work with finance and functional teams to develop operational plans, timelines, budgets, and resource plans and monitor performance against them.
  • Interface with and drive collaboration among functional teams and the Leadership Team on program-related matters.
  • Communicate program strategy, work product, updates, and issues to management and maintain the single source of truth for program topics and timelines.
  • Act as the point person for alliance management and coordination as needed.
  • Lead or manage strategic and platform-development projects and coordinate content for quarterly business review meetings with the Chief Scientific Officer and Research Leadership Team.
  • Collaborate with the Leadership Team on strategic plans, company goals, long-range planning assumptions, portfolio-level reports, and analyses supporting business processes and strategic discussions.
  • Develop and deliver presentations that distill complex issues into critical points and support strategic planning and decision-making.
  • Prepare strategic communications based on business strategy and issues, maintaining consistent content for executive communications and organizational goals.
  • Lead the Scientific Communications process with the Scientific Communications Committee.
  • Manage schedules, agendas, and content for Leadership Team, Board of Directors, and Town Hall meetings.
  • Identify opportunities for organizational improvements involving team structure, processes, and communication.
  • Support the CEO and Leadership Team with partnership discussions and negotiations, including research, presentation materials, diligence activities, and analysis of terms.
  • Map the competitive landscape and identify emerging competitive threats and opportunities.
  • Promote strategic discussions on external trends, competitor strategies, and potential disruptors and translate them into strategic recommendations.
  • Collect insights and intelligence through literature searches, analyst research, key opinion leader and patient-group interactions, and other sources.
Desired Qualifications
  • Experience developing advanced therapies to treat rare genetic disease.

Alltrna focuses on developing tRNA therapeutics to treat diseases caused by nonsense mutations. It decodes transfer RNA biology to regulate protein synthesis and restore full-length proteins that were truncated by stop codons. How it works: engineered tRNAs read premature stop codons and insert the correct amino acids during protein synthesis, enabling cells to produce full-length proteins despite genetic mutations. Differentiation: Unlike many biotech approaches, Alltrna centers on manipulating tRNA to fix the protein production step at its source. It positions itself as the first company to exploit tRNA biology for therapeutics, aiming to address thousands of diseases sharing the same nonsense mutation across patients. Goal: Create tRNA-based treatments that cure or alleviate diseases caused by nonsense mutations by re-establishing normal protein production in affected cells.

Company Size

11-50

Company Stage

Series B

Total Funding

$159M

Headquarters

Cambridge, Massachusetts

Founded

2018

Get referred to Alltrna

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Australia approved AP003 Phase 1 in March 2026, unlocking first human safety and PK data.
  • Alltrna still commands Flagship capital after its $109 million Series B in 2023.
  • The company added CSO David Hava in September 2025 and CMO Nerissa Kreher in January 2025.

What critics are saying

  • March 2026 layoffs cut 35% of staff, shrinking execution bandwidth before first-in-human data.
  • CEO Michelle Werner stepped down in March 2026, signaling leadership instability during clinical ramp.
  • AP003 targets rare Arg-TGA mutations only; failure in Australia ends the platform narrative.

What makes Alltrna unique

  • Alltrna’s AP003 became the first tRNA therapeutic to enter human trials, March 31 2026.
  • Its liver-directed LNP delivery uses Acuitas’ clinically tested platform, accelerating translational credibility.
  • Flagship Pioneering backing and AI/ML tRNA design tools differentiate Alltrna from conventional RNA shops.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Parental Leave

Unlimited Paid Time Off

401(k) Retirement Plan

Disability Insurance

Life Insurance

Commuter Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

4%

2 year growth

6%
PR Newswire
Mar 31st, 2026
Alltrna wins approval for first-ever tRNA therapeutic trial targeting Stop Codon Disease

Alltrna has received approval to initiate a Phase 1 clinical trial of AP003 in Australia, marking the first time a tRNA therapeutic has entered human trials. The study will evaluate safety and pharmacokinetics in healthy volunteers under Australia's Therapeutic Goods Administration Clinical Trial Notification scheme. AP003 is an engineered tRNA therapeutic designed to treat Stop Codon Disease caused by arginine-to-TGA premature termination codons. The therapy restores full-length protein production by inserting the correct amino acid at the mutation site. Preclinical studies have demonstrated the ability to restore protein expression whilst showing a safety profile consistent with established oligonucleotide and lipid nanoparticle therapies. Stop Codon Disease affects approximately 30 million people worldwide, representing 10% of all genetic disease patients. Data from this trial will inform future clinical development in patient populations.

PR Newswire
Sep 3rd, 2025
Alltrna Appoints David Hava, Ph.D., Chief Scientific Officer to Drive Strategic Pipeline Advancement of tRNA Medicines

CAMBRIDGE, Mass., Sept. 3, 2025 /PRNewswire/ - Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines to regulate the protein universe and resolve disease, today announced the appointment of David (Dave) Hava, Ph.D., as Chief Scientific Officer (CSO).

IT桔子
Aug 26th, 2025
ALLYRNA Secures $10M Seed Funding

ALLYRNA, an innovative small molecule drug developer focusing on first-in-class cancer treatments, has secured nearly $10 million in seed funding. The round was co-led by Qiji Investment, Gaorong, and Jifeng, with strategic follow-on investment from U.S.-based Plaisance Capital.

PR Newswire
Jan 7th, 2025
Alltrna Appoints Dr. Nerissa Kreher As Chief Medical Officer To Advance Trna Medicines For Rare Diseases

CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ -- Alltrna , a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Dr. Nerissa Kreher as Chief Medical Officer (CMO). Dr. Kreher brings decades of expertise in rare disease drug development, including extensive experience in clinical development, medical affairs, and regulatory strategy across both early- and late-stage programs."We are thrilled to welcome Nerissa to the Alltrna leadership team as we advance our first tRNA development candidates to the clinic for liver Stop Codon Disease," said Michelle C. Werner, CEO of Alltrna

PR Newswire
Apr 22nd, 2024
Alltrna Announces Presentations At Asgct 27Th Annual Meeting And Tides Usa 2024

CAMBRIDGE, Mass., April 22, 2024 /PRNewswire/ -- Alltrna , a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11 in Baltimore and a talk and two poster presentations at TIDES USA 2024 taking place May 14-17 digitally and in-person in Boston.Details of the presentations are as follows:ASGCT 27th Annual MeetingPoster Title: tRNA Therapeutics to Treat Stop Codon DiseaseSession Date & Time: May 9, 12:00 PM to 7:00 PM ETPresenter: Stephen Eichhorn, Ph.D., Head of Computational and Molecular Biology, AlltrnaPresentation Room: Exhibit HallSession Title: Oligonucleotide TherapeuticsAbstract Number: 1221TIDES USA 2024Talk Title: Manufacturing Strategies for Chemically Modified tRNAsSession Date & Time: May 17, 5:00 PM to 5:30 PM ETPresenter: William Kiesman, Ph.D., Chief Technology Officer, AlltrnaSession Title: Oligonucleotide Chemistry, Manufacturing, and ControlsPoster Title: Building 3-D homology models to support tRNA structure-based drug designPresenter: Audrey Hughes, Ph.D., Scientist II, Computational Chemistry, AlltrnaPoster Title: Quantification of Tissue Delivery for tRNA Therapeutics in LNP FormulationsPresenter: W. George Lai, Ph.D., Head of DMPK, Drug Safety and Clinical Pharmacology, AlltrnaPosters will be displayed onsite in the exhibit hall throughout TIDES USA 2024.About Stop Codon DiseaseStop Codon Disease encompasses thousands of rare and common diseases that stem from premature termination codons (PTC) also called nonsense mutations, where the code for an amino acid has been mutated into a premature "stop" codon. This results in a truncated or shortened protein product with no or altered biological activity that causes disease. Approximately 10% of all people with a genetic disease have Stop Codon Disease, representing approximately 30 million people worldwide. Alltrna is engineering tRNA medicines that can read these PTC mutations and deliver the desired amino acid, thereby restoring the production of the full-length protein.About AlltrnaAlltrna unlocks tRNA biology to treat disease. The company's platform incorporates AI/ML tools to develop and deliver diverse programmable molecules with broad therapeutic potential